UBS initiates Elekta stock with Sell rating, citing market headwinds

UBS has initiated coverage on Swedish medical equipment manufacturer Elekta AB (EKTAB) with a Sell rating and a price target of SEK34.00. The investment bank cited concerns over slowing market growth in the radiotherapy sector, where Elekta is the second-largest player, and expressed skepticism that the company's new Evo platform can counteract structural headwinds. UBS believes consensus earnings estimates are 9-19% too high and projects approximately 30% downside potential for the stock from current levels, despite its 20% year-to-date decline.

Analysis

UBS has initiated coverage on Swedish medical equipment manufacturer Elekta AB (ST:EKTAB) with a decidedly bearish outlook, issuing a Sell rating and a SEK34.00 price target. The core of the thesis rests on a combination of macroeconomic and company-specific headwinds. UBS analysis indicates a slowdown in market growth for the radiotherapy sector, a critical segment where Elekta is the second-largest global player and which constitutes 40% of its sales. Furthermore, the bank expresses significant doubt that Elekta's new Evo platform can effectively reverse a decade-long trend of market share losses to industry leader Varian, citing structural challenges in the market that may blunt the platform's impact. This skepticism translates into a material disconnect with market expectations; UBS believes consensus earnings estimates are inflated by 9-19%. Consequently, the firm projects approximately 30% further downside for the stock, a severe forecast considering the shares have already declined 20% year-to-date.

Key Decisions for Investors

• Given the projected 30% downside and UBS's view that consensus earnings are 9-19% too high, investors holding Elekta AB should consider reducing exposure or reassessing their thesis.
• The combination of slowing market growth, structural headwinds, and skepticism over the new Evo platform's ability to regain market share presents a potential short opportunity for bearish investors.
• Monitor upcoming earnings reports for any revisions to guidance and track early adoption data for the Evo platform, as these will be key indicators to either validate or refute UBS's bearish stance on the company's competitive position.